Abstract:The CDKN2A/B genomic locus is associated with risk of human cancers and metabolic disease. Although the locus contains several important protein-coding genes, studies suggest disease roles for a lesser-known antisense lncRNA encoded at this locus, called ANRIL. ANRIL is a complex gene containing at least 21 exons in simians, with many reported linear and circular isoforms. Like other genes, abundance of ANRIL is regulated by epigenetics, classic transcription regulation, splicing, and post-transcriptional influences such as RNA stability and microRNAs. Known molecular functions of ANRIL include in cis and in trans gene regulation through chromatin modification complexes, and influence over microRNA signaling networks. Polymorphisms at the ANRIL gene are linked to risk for many different cancers, as well as risk of atherosclerotic cardiovascular disease, bone mass, obesity and type 2 diabetes. A broad array of variable reported impacts of polymorphisms on ANRIL abundance, splicing and function suggests that ANRIL has cell-type and context-dependent regulation and actions. In cancer cells, ANRIL gain of function increases proliferation, metastasis, cell survival and epithelial-mesenchymal transformation, whereas ANRIL loss of function decreases tumor size and growth, invasion and metastasis, and increases apoptosis and senescence. In metabolic disease, polymorphisms at the ANRIL gene are linked to risk of type 2 diabetes, coronary artery disease, coronary artery calcium score, myocardial infarction, and stroke. Intriguingly, with the exception of one polymorphism in exon 2 of ANRIL, the single nucleotide polymorphisms (SNPs) associated with atherosclerosis and diabetes are non-overlapping. Evidence suggests that ANRIL gain of function increases atherosclerosis; in diabetes, a risk-SNP reduced the pancreatic beta cell proliferation index. Studies are limited by the uncertain relevance of rodent models to ANRIL studies, since most ANRIL exons do not exist in mouse. Diverse cell-type-dependent results suggest it is necessary to perform studies in the relevant primary human tissue for each disease. Much remains to be learned about the biology of ANRIL in human health and disease; this research area may lead to insight into disease mechanisms and therapeutic approaches.

Long Noncoding RNA ANRIL: a Potential Novel Prognostic Marker in Cancer: a Meta-Analysis.

Long Noncoding RNA ANRIL As a Novel Biomarker of Lymph Node Metastasis and Prognosis in Human Cancer: a Meta-Analysis

Long Noncoding RNA DANCR in Various Cancers: a Meta-Analysis and Bioinformatics.

Multiple Non-coding ANRIL Transcripts Are Associated with Risk of Coronary Artery Disease: a Promising Circulating Biomarker

ANRIL: a pivotal tumor suppressor long non-coding RNA in human cancers

Identification of anoikis-related lncRNAs and analysis of immune infiltration in patients with breast cancer

Long noncoding RNA ANRIL indicates a poor prognosis of gastric cancer and promotes tumor growth by epigenetically silencing of miR-99a/miR-449a.

Long Non-Coding RNA ANRIL Predicts Poor Prognosis and Promotes Invasion/metastasis in Serous Ovarian Cancer.

LncRNA-ANRIL Promotes Gastric Cancer Progression by Enhancing NF-kB Signaling.

Erratum To: Long Non-Coding RNA ANRIL is Upregulated in Hepatocellular Carcinoma and Regulates Cell Proliferation by Epigenetic Silencing of KLF2

ANRIL: A lncRNA at the CDKN2A/B Locus With Roles in Cancer and Metabolic Disease

Long Non-Coding Rna Anril Promotes Tumorigenesis In Glioma Via Mapk Signaling Pathways

Abstract 157: LncRNA ANRIL Indicates a Potential Prognostic Biomarker in Gastric Cancer and Promotes Tumor Growth by Silencing of Mir-99A/mir-449a

Circulating Exosomal ANRIL is a Novel Prognostic Marker for Epithelial Ovarian Cancer

Expression Level and Clinical Significance of NKILA in Human Cancers: A Systematic Review and Meta-Analysis

Black tea (Camellia sinensis) as a chemopreventive agent in oral precancerous lesions.

The Long Non-Coding RNA ANRIL Promotes Proliferation and Cell Cycle Progression and Inhibits Apoptosis and Senescence in Epithelial Ovarian Cancer

Prognostic Value of Lncrna AFAP1-AS1 in Breast Cancer: a Meta-Analysis and Validated Study in Chinese Population

An angiogenesis-related lncRNA signature predicts the immune microenvironment and prognosis of breast cancer

Supplementary Figure 1 from Long Noncoding RNA ANRIL Promotes Non–Small Cell Lung Cancer Cell Proliferation and Inhibits Apoptosis by Silencing KLF2 and P21 Expression

Alternative splicing‐related long noncoding RNA ANRIL facilitates hepatocellular carcinoma by targeting the miR‐199a‐5p/SRSF1 axis and impacting Anillin